TD Cowen analyst Tyler Van Buren says longer follow-up from the Phase 3 mRNA-1345 trial at ReSViNET suggests that Moderna’s (MRNA) RSV vaccine efficacy is declining quicker than the GSK (GSK) and Pfizer (PFE) vaccines. While noting the comparison of slightly different endpoints, the firm is concerned this could negatively affect mRNA-1345’s profile if confirmed with additional data. The firm has a Market Perform rating and $75 price target on Moderna shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA: